WallStreetZenWallStreetZen

NASDAQ: CELU
Celularity Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CELU

Based on 1 analyst offering 12 month price targets for Celularity Inc

Min Forecast
$6.00+354.55%
Avg Forecast
$6.00+354.55%
Max Forecast
$6.00+354.55%

Should I buy or sell CELU stock?

Based on 1 analyst offering ratings for Celularity Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CELU stock forecasts and price targets.

CELU stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-09

1 of 1

Forecast return on equity

Is CELU forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is CELU forecast to generate an efficient return on assets?

Company
-69.56%
Industry
10.97%
CELU is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CELU earnings per share forecast

What is CELU's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$4.96
Avg 2 year Forecast
-$2.81

CELU revenue forecast

What is CELU's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$25.5M-37.16%
Avg 2 year Forecast
$44.9M+10.6%
CELU's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CELU revenue growth forecast

How is CELU forecast to perform vs Biotechnology companies and vs the US market?

Company
-37.16%
Industry
9,299.51%
Market
1,426.08%
CELU's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CELU's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CELU vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CELU$1.32$6.00+354.55%Buy
TVRD$3.98$47.50+1,093.47%Strong Buy
RNTX$1.42$10.00+604.23%Buy
XCUR$5.88N/AN/A
QTTB$3.03N/AN/A
View Top Biotech Stocks

Celularity Stock Forecast FAQ

Is Celularity Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CELU) stock is to Buy CELU stock.

Out of 1 analyst, 0 (0%) are recommending CELU as a Strong Buy, 1 (100%) are recommending CELU as a Buy, 0 (0%) are recommending CELU as a Hold, 0 (0%) are recommending CELU as a Sell, and 0 (0%) are recommending CELU as a Strong Sell.

If you're new to stock investing, here's how to buy Celularity stock.

What is CELU's earnings growth forecast for 2025-2026?

(NASDAQ: CELU) Celularity's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 200.62%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 2,932.94%.

Celularity's earnings in 2025 is -$80,706,000.On average, 3 Wall Street analysts forecast CELU's earnings for 2025 to be -$140,431,924, with the lowest CELU earnings forecast at -$134,924,790, and the highest CELU earnings forecast at -$144,562,275.

In 2026, CELU is forecast to generate -$79,462,508 in earnings, with the lowest earnings forecast at -$76,346,332 and the highest earnings forecast at -$81,799,641.

What is CELU's revenue growth forecast for 2025-2026?

(NASDAQ: CELU) Celularity's forecast annual revenue growth rate of -37.16% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 9,299.51%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,426.08%.

Celularity's revenue in 2025 is $40,578,000.On average, 3 Wall Street analysts forecast CELU's revenue for 2025 to be $722,386,440, with the lowest CELU revenue forecast at $694,057,560, and the highest CELU revenue forecast at $743,633,100.

In 2026, CELU is forecast to generate $1,271,400,134 in revenue, with the lowest revenue forecast at $1,221,541,306 and the highest revenue forecast at $1,308,794,256.

What is CELU's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: CELU) forecast ROA is -69.56%, which is lower than the forecast US Biotechnology industry average of 10.97%.

What is CELU's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CELU price target, the average CELU price target is $6.00, with the highest CELU stock price forecast at $6.00 and the lowest CELU stock price forecast at $6.00.

The Wall Street analyst predicted that Celularity's share price could reach $6.00 by Sep 9, 2026. The average Celularity stock price prediction forecasts a potential upside of 354.55% from the current CELU share price of $1.32.

What is CELU's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: CELU) Celularity's current Earnings Per Share (EPS) is -$3.33. On average, analysts forecast that CELU's EPS will be -$4.96 for 2025, with the lowest EPS forecast at -$4.76, and the highest EPS forecast at -$5.10. In 2026, CELU's EPS is forecast to hit -$2.81 (min: -$2.70, max: -$2.89).

What is CELU's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: CELU) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.